Immunohistochemical Analysis of Human Equilibrative Nucleoside Transporter-1 (hENT1) Predicts Survival in Resected Pancreatic Cancer Patients Treated with Adjuvant Gemcitabine Monotherapy

CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC)

(2017) P. Neuhaus et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection

(2010) John P. Neoptolemos et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Current Status of Adjuvant Therapy for Pancreatic Cancer

(2010) M. H. G. Katz et al.   ONCOLOGIST

Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma

(2009) R. Marechal et al.   CLINICAL CANCER RESEARCH

Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer

(2008) James J. Farrell et al.   GASTROENTEROLOGY

Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation Following Resection of Pancreatic Adenocarcinoma

(2008) William F. Regine et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION